Loading...

NKGEN BIOTECH INC Delisting Actions 8-K Filing

NKGN

NKGEN BIOTECH INC

()

2024 8-K

Funding Agreement Update

Financial Agreements Update

Funding Amendment

Secured Promissory Note

Consulting Agreement

Stock Purchase Agreement

Acquisition Completed

Asset Acquisitions

Asset Acquisitions

Equity Offerings

Equity Investments

Equity Offerings

Loan Agreement Update

Convertible Loan Agreement

Stock Split Approval

Nasdaq Compliance

Acquisition Update

Convertible Loan Agreement

Stock Options Granted

Nasdaq Compliance Notice

Acquisition Agreement

Nasdaq Compliance Notice

Employee Furlough

Nasdaq Delisting Appeal

Stock Conversion

Director Appointments

Director Resignations

Nasdaq Compliance Issue

Delisting Notice

Nasdaq Delisting Notice

Agreement Amendments

Investment Conference

Nasdaq Compliance Issue

Management Change

Investment Agreement

Amendment to Forward Purcha...

Amendment to Forward Purcha...

Changes in Registrant's Cer...

Amendment to Forward Purcha...

Appointment of Director

Material Definitive Agreement

Amendment to Securities Pur...

Promissory Notes and Common...

Material Definitive Agreement

Amendment to Forward Purcha...

Equity and Business Loan Ag...

Promissory Notes and Common...

Promissory Notes and Common...

Management Change

Delisting Notice

Amendment to Forward Purcha...

Agreement Amendment

Resignation of Director

Amendment to Forward Purcha...

Amendment to Forward Purcha...

Amendment to Forward Purcha...

FDA Approval for Clinical T...

Amendment to Forward Purcha...

Financial Results Announcement

Regulation FD Disclosure

FDA Clearance for SNK01 Nat...

Amendment Filing

Merger Agreement

Shareholder Meeting

Merger Agreement and Forwar...

Merger Agreement and Adjour...

Merger Agreement and Warran...

Merger Agreement and Securi...

Adjournment of Special Meeting

Adjournment of Special Meeting

Merger Agreement

Merger Announcement

Merger Agreement and Clinic...

Merger Agreement

Shareholder Meeting

Merger Agreement

Restatement of Financial St...

Business Combination

External Links:

NKGen Biotech, Inc. received a delisting notice from Nasdaq due to failing to meet the $50 million market value requirement but plans to appeal and transfer to the Nasdaq Capital Market, which has a lower requirement of $35 million.

AI Assistant

NKGEN BIOTECH INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.